Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper (Q31034415)

28 June 2017

Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper (English)

1 reference

28 June 2017

1 reference

22

A Eggermont

0 references

Jean-Charles Soria

20

J-C Soria

0 references

Aurélien Marabelle

23

A Marabelle

0 references

Caroline Robert

21

C Robert

0 references

J-M Michot

J-M Michot

18

1 reference

ORCID Public Data File 2021

author name string

S Champiat

1

1 reference

28 June 2017

O Lambotte

2

1 reference

28 June 2017

E Barreau

3

1 reference

28 June 2017

R Belkhir

4

1 reference

28 June 2017

A Berdelou

5

1 reference

28 June 2017

F Carbonnel

6

1 reference

28 June 2017

C Cauquil

7

1 reference

28 June 2017

P Chanson

8

1 reference

28 June 2017

M Collins

9

1 reference

28 June 2017

A Durrbach

10

1 reference

28 June 2017

S Ederhy

11

1 reference

28 June 2017

S Feuillet

12

1 reference

28 June 2017

H François

13

1 reference

28 June 2017

J Lazarovici

14

1 reference

28 June 2017

J Le Pavec

15

1 reference

28 June 2017

E De Martin

16

1 reference

28 June 2017

C Mateus

17

1 reference

28 June 2017

D Samuel

19

1 reference

28 June 2017

J-C Soria

20

1 reference

28 June 2017

A Marabelle

23

1 reference

28 June 2017

28 December 2015

1 reference

28 June 2017

1 reference

28 June 2017

27

1 reference

28 June 2017

559-574

1 reference

28 June 2017

4

1 reference

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

28 June 2017

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

Management of immune-related adverse events and kinetics of response with ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

Ipilimumab-induced toxicities and the gastroenterologist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

Association between ipilimumab and celiac disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

Organizing pneumonia as a side effect of ipilimumab treatment of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

Pulmonary sarcoid-like granulomatosis induced by ipilimumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

Peripheral neuropathy associated with ipilimumab: a report of 2 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

Ipilimumab-induced necrotic myelopathy in a patient with metastatic melanoma: A case report and review of literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

Anti-cytotoxic T-cell lymphocyte antigen-4-induced regression of spinal cord metastases in association with renal failure, atypical pneumonia, vision loss, and hearing loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

Ipilimumab granulomatous interstitial nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

Kidney injuries related to ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

Serious haematological toxicity during and after ipilimumab treatment: a case series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

Ipilimumab-induced thrombocytopenia in a patient with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

Treatment possibilities of ipilimumab-induced thrombocytopenia--case study and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

Large granular lymphocytosis with severe neutropenia following ipilimumab therapy for metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

Febrile neutropenia in a metastatic melanoma patient treated with ipilimumab - case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

Ipilimumab-induced autoimmune pancytopenia in a case of metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

Vogt-Koyanagi-Harada-like syndrome after CTLA-4 inhibition with ipilimumab for metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

Retinal vasculitis and ocular vitreous metastasis following complete response to PD-1 inhibition in a patient with metastatic cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

Orbital myositis associated with ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

Thyroid-like ophthalmopathy in a euthyroid patient receiving Ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

Diagnosis and classification of drug-induced autoimmunity (DIA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

Ipilimumab in patients with melanoma and autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

Ipilimumab administration in patients with advanced melanoma and hepatitis B and C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

Ipilimumab-induced hepatitis C viral suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

Drugs and autoimmunity--a contemporary review and mechanistic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

Nivolumab in previously untreated melanoma without BRAF mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

Opportunistic infections in patients treated with immunotherapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

Anti-CTLA4 antibody-induced lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

Neurological immune-related adverse events of ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

A severe case of ipilimumab-induced guillain-barré syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV623

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDV623

1 reference

28 June 2017

1 reference